Roivant Sciences is facing questions about whether its business model can survive its recent successes. The company’s drug brepocitinib showed positive results in a study for non-infectious uveitis, while also announcing a $1.5 billion stock buyback, including shares owned by Sumitomo. Many of Roivant’s drugs, including brepocitinib, were initially part of larger pharmaceutical companies like Pfizer before being developed by Roivant subsidiaries. The success of Roivant’s model can be seen in the recent acquisition of Televant by Roche for $7.1 billion. Whether Roivant’s unique approach to drug development will continue to thrive remains to be seen.
Source link
STAT+: Roivant CEO: New deals could ‘materialize later this year’
